요관경 시장 : 제품 유형별, 용도별, 기술별, 용도 분야별, 최종 사용자별 시장 예측(2026-2032년)

The Ureteroscope Market is projected to grow by USD 1.91 billion at a CAGR of 9.16% by 2032.

The ureteroscope market is anchored by the growing global burden of urinary stone disease, expanding endourology programs, and sustained demand for minimally invasive urological care. Kidney stones are among the most common urologic disorders, with the National Kidney Foundation citing that more than one in ten people in the United States will develop a kidney stone during their lifetime, while peer-reviewed epidemiology consistently shows rising incidence linked to obesity, diabetes, dehydration, diet, and warmer climates.

Ureteroscopes, including flexible, semi-rigid, reusable, and single-use platforms, are central to ureteroscopy for diagnosing and treating ureteral and renal stones. Adoption is supported by American Urological Association and European Association of Urology guidance that recognizes ureteroscopy as a key treatment option for many ureteral and intrarenal stones, particularly as laser lithotripsy, digital imaging, and smaller scope diameters improve procedural precision, stone management, and patient recovery.

Transformative Shifts in the Ureteroscope Landscape

The ureteroscope landscape is shifting from conventional reusable systems toward a more balanced ecosystem that includes digital flexible ureteroscopes, disposable ureteroscopes, high-definition visualization, and integrated laser compatibility. Hospitals are reassessing total cost of ownership as reusable scopes require repair, sterilization, tracking, and downtime management, while single-use devices offer predictable performance and reduced reprocessing burden.

Clinical practice is also moving toward outpatient and ambulatory surgical settings as anesthesia protocols, miniaturized instruments, and same-day discharge pathways mature. These shifts are reinforced by infection-control expectations, central sterile processing constraints, and growing pressure to improve operating room efficiency without compromising safety, visualization quality, or stone-free outcomes.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across the ureteroscope workflow rather than replacing physician decision-making. In preoperative planning, AI-supported imaging analytics can assist stone detection, volume estimation, and risk stratification using CT and ultrasound data. During procedures, computer vision research is advancing stone recognition, anatomical orientation, image enhancement, and automated documentation, helping reduce cognitive load in complex ureteroscopy cases.

Operationally, AI can strengthen case scheduling, scope utilization forecasting, repair prediction, and inventory planning for reusable and single-use ureteroscope fleets. The strongest near-term impact is expected in decision support, quality analytics, and procedural standardization, provided systems remain clinically validated, compliant with medical device regulations, and transparent for urologists, hospital administrators, and procurement teams.

Key Regional Insights for Ureteroscope Adoption

Asia-Pacific represents one of the most dynamic environments for ureteroscope adoption, supported by large patient pools in China and India, advanced endourology capacity in Japan, South Korea, and Australia, and increasing private hospital investment across Southeast Asia. High population density, urban diets, diabetes prevalence, and uneven hydration patterns are contributing to higher stone disease recognition and procedure volumes, making flexible ureteroscopy, laser lithotripsy, and cost-effective device access important priorities across the region.

North America remains a high-value environment due to established urology networks, guideline-driven care, advanced laser adoption, ambulatory surgical capabilities, and strong reimbursement infrastructure. Europe benefits from mature endoscopic surgery standards and European Union medical device regulation that emphasizes clinical evidence, safety, post-market surveillance, and traceability. Latin America is expanding through Brazil and Mexico as tertiary centers and private hospitals invest in flexible ureteroscopy, while the Middle East shows elevated relevance because several countries sit within the global stone belt, where hot climates and dehydration risk increase clinical need. Africa remains earlier in adoption, with demand concentrated in urban referral hospitals and constrained by equipment availability, trained specialists, financing, and sterilization capacity.

Key Group Insights Across Global Healthcare Blocs

ASEAN is becoming increasingly important as Indonesia, Thailand, Vietnam, Malaysia, and the Philippines expand hospital infrastructure, specialist training, and medical tourism capabilities, creating demand for cost-effective ureteroscope platforms, durable service models, and practical clinical education. The GCC has a strong clinical need due to high stone prevalence associated with hot climates, dehydration risk, and metabolic disease; premium hospitals in Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait are receptive to advanced digital ureteroscopes, single-use systems, and laser-compatible platforms that support efficient stone management.

The European Union emphasizes compliance with the EU Medical Device Regulation, sustainability, procurement transparency, and evidence-based adoption, making durability, lifecycle cost, clinical validation, and post-market performance central to vendor success. BRICS countries combine large untreated demand with expanding domestic manufacturing, hospital modernization, and public healthcare investment, while the G7 remains a hub for premium innovation, clinical research, guideline-aligned practice, and early adoption of digital endourology. NATO markets overlap significantly with high-income procurement systems where supply resilience, cybersecurity, device traceability, sterile processing reliability, and continuity of care influence purchasing decisions.

Key Country Insights for Ureteroscope Demand

The United States leads in procedure volume, innovation adoption, laser lithotripsy use, and ambulatory ureteroscopy, while Canada shows steady uptake through publicly funded hospital systems focused on outcomes, safety, and cost control. Mexico and Brazil are important Latin American markets where private hospitals and tertiary public centers are expanding access to flexible ureteroscopy and minimally invasive stone treatment. The United Kingdom, Germany, France, Italy, and Spain maintain sophisticated urology networks, with Germany particularly strong in medical technology evaluation, procedural standardization, and hospital procurement discipline, while France and the United Kingdom emphasize guideline-aligned care pathways, infection control, and health system efficiency.

Russia retains demand across major urban centers despite procurement and import constraints, with access shaped by regional hospital budgets and specialist availability. China and India are among the most consequential growth markets because of scale, rising diagnosis, urbanization, diabetes burden, and hospital modernization. Japan and South Korea prioritize high-quality visualization, precision instruments, compact device design, and advanced endourology training, while Australia benefits from strong specialist networks, modern hospital infrastructure, and adoption of minimally invasive stone management across metropolitan and referral hospitals.

Actionable Recommendations for Industry Leaders

Industry leaders should align product portfolios with real-world clinical and operational needs. This includes offering both reusable and single-use ureteroscope options, strengthening service models, providing transparent repair economics, supporting sterilization workflows, and ensuring compatibility with holmium and thulium fiber laser systems. Vendors should invest in physician training, simulation, and proctoring because clinical confidence directly affects adoption, utilization, and repeat purchasing.

Manufacturers and distributors should also prioritize evidence generation, infection-control documentation, device durability data, and lifecycle cost studies for hospital procurement teams. In growth markets, modular pricing, local service capacity, distributor quality, and partnerships with urology societies can accelerate access. For AI-enabled features, companies should pursue clinically validated, regulator-ready tools that improve workflow, image quality, stone recognition, and documentation without overclaiming autonomous capability.

Research Methodology

The research methodology integrates secondary research, expert validation, and triangulated market intelligence. Secondary inputs include urology guidelines from the American Urological Association and European Association of Urology, regulatory databases from authorities such as the U.S. FDA and European regulators, hospital procurement patterns, peer-reviewed epidemiology, device safety information, reimbursement references, clinical literature, and public disclosures from medical technology manufacturers.

Primary validation typically includes interviews with urologists, endourology specialists, procurement managers, distributors, biomedical engineers, and sterile processing stakeholders. Findings are triangulated across procedure trends, installed base indicators, regulatory approvals, reimbursement context, clinical adoption patterns, and competitive product positioning. This approach supports data-backed insight while avoiding unsupported claims and ensuring that interpretation reflects clinical, operational, regulatory, and regional realities.

Conclusion

The ureteroscope market is positioned for sustained relevance as stone disease continues to rise and healthcare systems prioritize minimally invasive, efficient, and guideline-supported urological care. Technology advances in flexible digital imaging, laser lithotripsy, single-use ureteroscopes, improved sterilization practices, and AI-enabled workflow tools are reshaping clinical practice and procurement decisions.

Success will depend on balancing performance, safety, economics, and access. Organizations that provide validated technology, strong service support, region-specific pricing, reliable training, and credible clinical education will be best positioned to meet demand across mature markets and emerging healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Ureteroscope Market, by Product Type

• 7.1. Flexible
• 7.2. Rigid
• 7.3. Semi-Rigid

8. Ureteroscope Market, by Usage

• 8.1. Reusable
• 8.2. Single-Use

9. Ureteroscope Market, by Technology

• 9.1. Digital
  • 9.1.1. 2D
  • 9.1.2. 3D
• 9.2. Fiber Optic
  • 9.2.1. High-Definition
  • 9.2.2. Standard

10. Ureteroscope Market, by Application

• 10.1. Diagnostic
  • 10.1.1. Biopsy
  • 10.1.2. Imaging
• 10.2. Therapeutic
  • 10.2.1. Stent Placement
  • 10.2.2. Stone Removal
  • 10.2.3. Tumor Ablation

11. Ureteroscope Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Clinics
• 11.3. Hospitals

12. Ureteroscope Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Ureteroscope Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Ureteroscope Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Advin Health Care
• 16.2. Becton, Dickinson and Company
• 16.3. Boston Scientific Corporation
• 16.4. Dornier MedTech GmbH
• 16.5. E.M.S. Electro Medical Systems S.A.
• 16.6. ELMED Medical Systems
• 16.7. ERBE Elektromedizin GmbH
• 16.8. Karl Storz Medical AG
• 16.9. Obex
• 16.10. Olympus Corporation
• 16.11. OPCOM
• 16.12. OTU Medical Inc.
• 16.13. PENTAX Medical
• 16.14. Prosurg Inc.
• 16.15. Richard Wolf GmbH
• 16.16. Rocamed
• 16.17. SCHOLLY FIBEROPTIC GMBH
• 16.18. Stryker Corporation
• 16.19. Vimex Sp. z o.o